Bristol-Myers Squibb has selected Medidata’s Clinical Cloud to help manage, monitor and analyse its clinical trials data
Medidata’s Clinical Cloud technology platform will support Bristol-Myers Squibb’s research capabilities in immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, genetically modified diseases and metabolics.
Bristol-Myers Squibb will integrate Medidata’s data management, data analytics and risk-based monitoring (RBM) capabilities into all stages of its drug development process, according to Medidata.
Medidata’s chief executive officer, Tarek Sherif, said: “Our agreement with Bristol-Myers Squibb is a great example of how the world’s best clinical researchers are increasingly relying on Medidata technology to help support advances in treatments for patients.
“Medidata has developed the most comprehensive cloud platform dedicated to clinical research, powered by the world’s largest data repository.
“With our powerful and flexible SaaS solution, we are helping our customers achieve meaningful time-to-market results, as well as giving them the data and actionable insights they need to innovate successfully.”
Medidata said that through its Clinical Cloud platform, Bristol-Myers Squibb will be able to use a full suite of Medidata solutions, including Medidata Rave for electronic data capture, management and reporting as well as Medidata’s RBM solutions, Medidata TSDV and Medidata CSA.